Based on the results presented herein, DAB2IP may be able to differentiate the worst cases amongst the already high‐risk group of prostate cancer patients that are at greatest risk for treatment failure prior to initiation of standard therapy. This evidence concerns the gene DAB2IP and prostate carcinoma.